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A B S T R A C T
Hepatitis B virus (HBV) is endemic in Africa, where it may occur as an HIV coinfection. Data re-
main limited on HIV–HBV epidemiology in Africa, particularly in children. Using programmatic
data from pediatric HIV clinics in Lusaka, Zambia during 2011–2014, we analyzed the prevalence of
chronic HBV coinfection (defined as a single positive hepatitis B surface antigen [HBsAg] test) and
its impact on immune recovery and liver enzyme elevation (LEE) during the first year of antiretro-
viral therapy. Among 411 children and adolescents, 10.4% (95% confidence interval, 7.6–14.1) had
HIV–HBV. Coinfected patients were more likely to have World Health Organization stage 3/4,
LEE and CD4 <14% at care entry (all p< 0.05). During treatment, CD4 increases and LEE inci-
dence were similar by HBsAg status. HBsAg positivity decreased (11.8% vs. 6.6%; p¼ 0.24) follow-
ing HBV vaccine introduction. These findings support screening pediatric HIV patients in Africa for
HBV coinfection. Dedicated cohorts are needed to assess long-term outcomes of coinfection.
K E Y W O R D S : HIV, Hepatitis B, Developing Countries
B A C K G R O U N D
Worldwide, 240 million individuals have chronic
hepatitis B virus infection (CHB), with most occur-
ring in Asia and sub-Saharan Africa (SSA) [1].
Individuals who develop CHB in childhood have a
25% lifetime risk of premature death from
complications of chronic liver disease, including hep-
atocellular carcinoma [2]. In SSA, an estimated 3 mil-
lion CHB patients are dually HIV infected [3]. HIV
coinfection increases the risk of CHB and accelerates
hepatitis B virus (HBV)-related liver disease progres-
sion[4]. However, there are limited data on HIV–HBV
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epidemiology in SSA, particularly among children.
Most SSA countries incorporated HBV vaccine into
childhood immunization programs, but some reports
suggest that CHB remains relatively common among
HIV-infected children. We described the prevalence of
HIV–HBV among children born in the pre- and post-
vaccine eras and investigated the short-term treatment
outcomes of pediatric HIV–HBV in Zambia.
M E T H O D S
We analyzed data from Zambia’s capital Lusaka from
1 January 2011 to 28 February 2014, following dis-
semination of the Ministry of Health’s 2010 HIV
guidelines recommending hepatitis B surface antigen
(HBsAg) testing at enrollment [5]. We categorized
pediatric patients as children (0–9 years of age) or
adolescents (10–19 years of age) [6] and excluded
adults. To reduce selection bias, we excluded patients
from clinics where <10% of children were tested.
Per 2010 national guidelines, patients were antiretro-
viral therapy (ART) eligible if they were <2 years
old, 2–5 years old with a CD4 <25% or 5–19 years
old with a CD4 350 cells/mm [5, 7]. In addition,
all patients with World Health Organization (WHO)
stage 3/4 were ART eligible regardless of age or
CD4%/count.
Using multivariable logistic regression, we identi-
fied patient factors associated with HBsAg screening
at enrollment. Among HBsAg-tested patients, we
defined CHB as a single positive HBsAg test and
determined patient characteristics associated with
coinfection in multivariable models. Among the
group that was HBsAg tested and initiated ART, we
assessed the association of CHB with the odds of
CD4 >25% at 1 year of treatment. We also
described the incidence of liver enzyme elevation
(LEE; defined as alanine aminotransferase [ALT]
>45 U/L for patients <12 months old and >33 U/L
for all others) among ART recipients with normal
initial ALT. We compared the incidence of events
per 1000 person-years of treatment between those
with and without CHB.
We explored CHB prevalence over calendar time
in relation to the Ministry’s introduction of HBV
vaccine in 2005 [8]. We compared HBsAg positivity
between patients born before (1991–2005) and after
(2006–2013) vaccine availability using a chi-square
test. Statistical analyses were performed with SAS
version 9.3 (SAS Institute, Cary, NC). Ethics com-
mittees of the University of Zambia and University
of North Carolina at Chapel Hill approved the use
of programmatic data for this analysis.
R E S U L T S
Within 10 facilities, 2,010 HIV-infected children/ado-
lescents enrolled in HIV care. Of those, 411 (20.9%)
were HBsAg tested and comprised the analysis co-
hort. The odds of HBsAg testing was increased for
adolescents (adjusted odds ratio [AOR]: 2.50; 95%
confidence interval [CI]: 1.92–3.27); however, those
with WHO stage 3/4 were less likely to be tested
(AOR: 0.64; 95% CI: 0.48–0.84). Testing was unre-
lated to sex, body mass index, CD4 count, LEE or tu-
berculosis (all p> 0.05).
In the analysis cohort, 265 (64.5%) were female,
median CD4 was 15.6% (interquartile range: 10.2–
23.8) and 43 were HBsAg positive for a prevalence
of 10.5% (95% CI, 7.6–14.1). In adjusted analysis,
adolescence, LEE, CD4 <14% and WHO stage 3/4
were associated with CHB coinfection (all p< 0.05;
Table 1).
After enrollment, 257 (62.5%) patients initiated
ART and contributed 198.1 person-years of follow-
up. During the first year of ART, patients experi-
enced an average increase of 196 CD4 cells/mm3 or
8.3%. Baseline CD4 <14% was associated with
reduced odds of achieving CD4 25% at 1 year
(AOR: 0.06; 95% CI: 0.01–0.44); however, CHB did
not predict reduced immune recovery (AOR: 1.39,
95% CI: 0.38–4.93). At enrollment, 17 (16.7%) had
LEE, and during treatment, there were 13 incident
LEEs (1 among HBsAg positives and 12 among
HBsAg negatives), including 7 that were grade 2 or
greater, [9] for an overall incidence rate of 65.6 per
1000 person-years. Incidence of LEE was similar by
HBsAg status (65.0 vs. 65.7, p¼ 1.000). Children
born following implementation of routine HBV vac-
cination had a trend toward lower HBsAg positivity
(11.8% vs. 6.6%; p¼ 0.24).
D I S C U S S I O N
In urban Zambia, among those screened for HBV,
approximately 10% of pediatric HIV-infected pa-
tients had CHB, with slightly lower prevalence
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among those born since HBV immunization began.
Compared with HBsAg-negative patients, CHB
coinfected patients had more advanced HIV disease
and evidence of LEE at enrollment; however, short-
term ART outcomes appeared to be similar.
This is the first report from Zambia on pediatric
HIV–HBV, and the relatively large size of the cohort
allowed us to analyze ART outcomes, something lack-
ing in recent publications from SSA. Our analysis has
limitations, primarily arising from incomplete data, a
common programmatic issue in settings like ours.
Dissemination of HBsAg-testing guidelines was sub-
optimal [10] and only one-fifth of pediatric patients
were HBsAg tested; therefore, patients included in
analysis may represent a select population. However,
those with LEE at enrollment were not more likely to
be screened, suggesting that testing did not occur be-
cause of suspected liver disease. Adolescents were
more likely to be screened as some receive care in the
adult HIV clinic where there is greater awareness of
HBV. We also acknowledge that small sample sizes in
longitudinal analyses reduced our statistical power to
detect small differences in CD4 change and incident
LEEs by HBsAg status.
These results build on an emerging literature on
HIV–HBV in SSA. Our observation that CHB
coinfected patients had LEE, lower CD4 and more
advanced clinical status is similar to some SSA re-
ports, [11–14] but differs from others [11, 13, 15–
17]. Significant liver disease is uncommon in pediat-
ric CHB; however, the natural history of HIV–HBV
is less well described, particularly in SSA. CHB did
not appear to impact early treatment outcomes, but
these results require confirmation in other settings.
Our observed HIV–HBV prevalence of 10.5% is con-
sistent with reported prevalence of 1.2–12.1% in
other SSA settings [11–15, 17–22]. We observed
lower HBsAg positivity among children born in the
era of HBV immunization, similar to other low- and
middle-income countries [12, 23]. HBsAg testing
was inconsistent in our program;[10] therefore,
these data are not strong evidence of HBV vaccine
Table 1. Characteristics associated with HBsAg positivity among 411 HIV-infected children and
adolescents in Zambia screened for HBV at enrollment
Characteristic Number (%) HBsAg positive Crude odds ratio (95% CI) Adjusted Odds ratio (95% CI)
Age, in years
0–9 9 (7.4) Reference Reference
10–19 34 (11.7) 1.59 (0.78–3.56) 2.80 (1.13–7.93)
Sex
Male 18 (12.3) Reference Reference
Female 25 (9.4) 0.74 (0.39–1.41) 0.62 (0.28–1.37)
Body mass index
2 z score 24 (8.2) Reference Reference
<2 z score 12 (16.7) 2.26 (1.04–4.64) 1.57 (0.68–3.48)
WHO clinical stage
1 or 2 24 (9.0) Reference Reference
3 or 4 19 (15.0) 1.78 (0.93–3.36) 2.30 (1.07–4.91)
Tuberculosis
No 42 (10.7) Reference Reference
Yes 1 (5.9) 0.75 (0.08–3.13) 0.43 (0.04–2.20)
CD4 percentage
14% 14 (5.9) Reference Reference
<14% 29 (16.9) 3.15 (1.65–6.28) 3.34 (1.58–7.56)
ALT, in U/L
Normal 27 (8.0) Reference Reference
Elevated 15 (22.4) 3.32 (1.64–6.55) 2.96 (1.29–6.58)
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effectiveness, and further investigation is needed in
this area.
In summary, CHB coinfection was common
among HIV-infected children and adolescents in
Zambia, supporting the need for dedicated screening
and treatment guidelines for developing countries,
and cohort studies to characterize the long-term
ART outcomes of these at-risk patients.
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